Efavirenz: Enhancing the gold standard

International Journal of STD and AIDS

Volumn 14, Issue SUPPL. 1, 2003, Pages 6-14

  Arribas, J R ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Efavirenz; Efficacy; HIV infection

Indexed keywords

EFAVIRENZ; NEVIRAPINE; NUCLEOSIDE ANALOG; RITONAVIR;

ANXIETY; CENTRAL NERVOUS SYSTEM DISEASE; CONFERENCE PAPER; DEPRESSION; DISORIENTATION; DOSE RESPONSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; LONG TERM CARE; MAINTENANCE THERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RASH; SKIN TOXICITY; TREATMENT OUTCOME; TREATMENT PLANNING; VERTIGO; VIVID DREAM;

EID: 0242330269     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/095646203322491824     Document Type: Conference Paper

References (26)

1. Tashima K, Staszewski S, Morales-Ramirez J, et al. 3-Year durability of response with an efavirenz (EFV)-containing regimen: 144-week follow-up study 006 [Abstract 810]. 1st International AIDS Society Conference, Buenos Aires, 2001
2. Robbins G, Shafer R, Smeaton L, et al. Antiretroviral strategies in naïve HIV+ subjects: comparison of sequential 3-drug regimens (ACTG 384) [Abstract LbOr20A]. Fourteenth International AIDS Conference, Barcelona 2002
3. Squires KE, Thiry A, Giordano M. Atazanavir (ATV) QD and efavirenz (EFV) QD with fixed-dose ZDV+3TC: comparison of antiviral efficacy and safety through wk 24 (AI424-034) [Poster H-1076]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego 2002
4. Kempf D, King M, Bauer E, et al. Comparative incidence and temporal accumulation of PI and NRTI resistance in HIV-infected subjects receiving lopinavir/ritonaviror or nelfinavir as initial therapy [Abstract 600]. 10th Conference on Retroviruses and Opportunistic Infections, Boston 2003
5. Montaner J, Saag M, Barylski C, et al. FOCUS Study: saquinavir QD regimen versus efavirenz QD regimen 24 week analysis in HIV infected patients [Oral I-670]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago 2001
6. Bartlett JA, Johnson J, Herrera C, et al. Abacavir/lamivudine (ABC/3TC) in combination with efavirenz (NNRTI), amprenavir/ritonavir (PI) or stavudine (NRTI): ESS40001 (CLASS) preliminary 48 weeks results [Abstract TuOrB1190]. XIV International AIDS Conference, Barcelona 2002
7. Gulick RM, Ribaudo HJ, Shikuma CM, et al. ACTG 5095: A comparative study of 3 protease inhibitor-sparing antiretroviral regimens for the initial treatment of HIV infection [Abstract 41]. 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris 2003
8. Keiser P, Nassar N, Smillie J, et al. An observational cohort comparison of zidovudine-lamivudine-efavirenz to zidovudine-lamivudine-abacavir in anti-retroviral naïve individuals [Poster 554]. 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris 2003
9. van Leth F, Hassink E, Phanuphak P, et al. Results of the 2NN Study: A randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine [Abstract 176]. 10th Conference on Retroviruses and Opportunistic Infections, Boston 2003
10. Matthews GV, Sabin CA, Mandalia S, et al. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral naive patients: a cohort study. AIDS 2002;16:53-61
11. Matthews GV, Mandalia S, Orkin C, et al. Durability of efavirenz compared to nevirapine with long term follow-up of an antiretroviral naïve cohort (Poster 561). 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris 2003
12. Keiser P, Nassar N, White C, et al. Comparison of nevirapine-and efavirenz-containing antiretroviral regimens in antiretroviral-naive patients: a cohort study. HIV Clin Trials 2002;3:296-303
13. Phillips AN, Pradier C, Lazzarin A, et al. with EuroSIDA. Viral load outcome of non nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. AIDS 2001;15:2385-95
14. Nelson M, Staszewski S, Morales-Ramirez JO, et al. Successful virologic suppression with efavirenz in HIV-infected patients with low baseline CD4 cell counts: Post hoc results from study 006 [Abstract 3-349]. 10th European Congress of Clinical Microbiology and Infectious Diseases, Stockholm 2000
15. Arribas JR, Pulido F, Miro JM, et al. Comparative study of efavirenz or protease inhibitor-based HAART in HIV-infected patients with <100 CD4 cells/mL and opportunistic diseases (EFAVIP-2 study) [Abstract TuOrB1187]. XIV International AIDS Conference, Barcelona 2002
16. Katlama C, Rachlis A, Staszewski S, et al. Better virological suppression after substitution of protease inhibitors with efavirenz in patients with unquantifiable viral loads [Abstract 06]. 8th European Conference on Clinical Aspects and Treatment of HIV Infection, Athens 2001
17. Martinez E, Podzamczer D, Ribera E, et al. Switching protease inhibitors to nevirapine (NEV), efavirenz (EFA) or abacavir (ABA): A randomized, multicenter, open-label, simplification trial [Abstract LB17]. 9th Conference on Retroviruses and Opportunistic Infections, Seattle 2002
18. Maggiolo P, Migliorino M, Maserati R, et al. Once-a-day treatment for HIV infection: final 48-week results [Abstract 320]. 8th Conference on Retroviruses and Opportunistic Infections, Chicago 2001
19. Landman R, Thiam S, Canestri A, et al. Long-term evaluation (15 months) of ddl, 3TC and efavirenz once-daily regimen in treatment-naive patients in Senegal: ANRS 12-04/IMEA 011 study [Abstract 458-W]. 9th Conference on Retroviruses and Opportunistic Infections, Seattle 2002
20. Maggiolo F, Arici C, Gregis GP, et al. A controlled, randomised, prospective study on a once-a-day therapy for HIV [Abstract H-163]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego 2002
21. Molina JM, Ferchal F, Rancinan C, et al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J Infect Dis 2000;182:599-602
22. Molina J, Ferchal F, Rancinan C, et al. Once-daily combination of emtricitabine, didanosine, and efavirenz vs continued PI-based HAART in HIV-infected adults with undetectable plasma HIV-RNA: 48-week results of a prospective randomized multicenter trial (ALIZE-ANRS 99) [Abstract 551-P]. 10th Conference on Retroviruses and Opportunistic Infections, Boston 2003
23. Johnson M, Staszewski S, Nelson M, et al. Low incidence and prevalence of CNS and psychiatric adverse experiences with long term use of efavirenz. 8th European Conference on Clinical Aspects and Treatment of HIV Infection, Athens 2001
24. Sulkowski MS, Thomas DL, Mehta SH, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2003;35:182-9
25. van Leth F, Phanuphak P, Gazzard B, et al., for the 2NN study group. The 2NN lipid sub-study: Lipid changes in patients using first-line antiretroviral therapy regimens containing either nevirapine, efavirenz or both, together with stavudine and lamivudine [Poster 752]. 10th Conference on Retroviruses and Opportunistic Infections, Boston 2003
26. Reiss P. 10th Conference on Retroviruses and Opportunistic Infections, Boston 2003